DYN Stock Summary and Trading Ideas (Dyne Therapeutics | NASDAQ:DYN)

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Dyne Therapeutics trades on the NASDAQ stock market under the symbol DYN.

As of December 16, 2025, DYN stock price declined to $19.55 with 2,458,043 million shares trading.

DYN has a beta of 1.92, meaning it tends to be more sensitive to market movements. DYN has a correlation of 0.12 to the broad based SPY ETF.

DYN has a market cap of $3.16 billion. This is considered a Mid Cap stock.

In the last 3 years, DYN traded as high as $47.45 and as low as $6.36.

The top ETF exchange traded funds that DYN belongs to (by Net Assets): VTI, IWM, XBI, VB, VXF.

DYN has underperformed the market in the last year with a price return of -24.0% while the SPY ETF gained +13.6%. However, in the short term, DYN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +52.0% vs +3.0% return in SPY. But in the last 2 weeks, DYN shares have been beat by the market, returning -5.1% compared to an SPY return of -0.2%.

DYN support price is $18.46 and resistance is $20.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DYN shares will trade within this expected range on the day.